柏柏林与葡萄糖相结合,通过调节肠道微生物群和增加勒素敏感性,可以预防肥胖
Dan Wu1,2, Feng Zhang1, Huiying Wang1
1National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology (Central South University), Ministry of Education, and Department of Metabolism and Endocrinology, the Second Xiangya Hospital of Central South University, Changsha, 410011, China.
Science China. Life sciences
|October 12, 2025
概括
柏柏林和葡萄糖的组合可以通过调节肠道微生物群来改善瘦素敏感性,并通过调节肠道微生物群来降低肥胖小鼠的体重. 这种方法提高了氨酸水平,这是改善瘦素敏感性的关键因素.
科学领域:
- 代谢性疾病是一种代谢性疾病.
- 肠道微生物群研究研究
- 肥胖和新陈代谢
背景情况:
- 瘦素抵抗是肥胖的一个关键特征.
- 肠道微生物群影响勒素耐药性的发展和进展.
- 对肠道微生物群干预勒素敏感性的疗效需要进一步研究.
研究的目的:
- 为了研究柏柏林和葡萄糖对饮食诱导肥胖 (DIO) 小鼠的瘦素敏感性和体重的影响.
- 探索肠道微生物群调节在这个过程中的作用.
- 为了确定潜在的机制,包括精氨酸代谢,涉及到改善的瘦素敏感性.
主要方法:
- 饮食诱导肥胖 (DIO) 的小鼠模型.
- 柏柏林和稳糖的同时使用.
- 对肠道微生物群组成的分析.
- 评估宿主纯素代谢和下丘脑因素.
- 直接补充伊诺辛. 这是一种直接补充.
主要成果:
- 柏柏林和葡萄糖的组合增强了Leptin的敏感性,并降低了DIO小鼠的体重.
- 这种干预调节了肠道微生物群,增加了Blautia producta的丰富性.
- 柏柏林和葡萄糖改变了宿主纯素代谢,提高了氨酸水平.
- 单独服用伊诺辛补充剂可以缓解下丘脑炎症和内分泌网膜压力,改善瘦素敏感性.
结论:
- 柏柏林与稳糖相结合,作为肥胖症的新瘦素敏感剂.
- 该机制涉及肠道微生物群的调节和随后的宿主纯素代谢的改变,特别是涉及氨酸.
- 这种组合疗法提供了一种潜在的策略,通过提高勒素敏感性来管理肥胖.
相关概念视频
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
166
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
166
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
246
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
246
01:30Regulation of Food Intake
2.3K
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
2.3K
01:24Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
523
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
523